https://www.selleckchem.com/products/LY335979.html
The Chinese subset included 667 patients; of these, 363 (54%) received high-dose cisplatin. Baseline characteristics were comparable. While response rates were similar for NEPA and APR/GRAN during the acute, delayed and overall phases, significantly fewer NEPA patients experienced breakthrough CINV on individual Days 3-5 in both the Chinese patients and also in those receiving high-dose cisplatin. As a fixed oral NK1 RA/5HT3 RA combination given once/cycle, NEPA is a convenient highly effective prophylactic antiemetic that may offer be
Like
Comment
Share
